Leap Therapeutics Announces Collaboration With EORTC to Evaluate DKN-01 in Combination with PD-L1 Cancer Immunotherapy and Chemotherapy In Esophagogastric and Biliary Tract Cancers
Leap Therapeutics, Inc. (LPTX)
Last leap therapeutics, inc. earnings: 11/14 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.leaptx.com
Company Research
Source: GlobeNewswire
CAMBRIDGE, Mass., Sept. 08, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced an immunotherapy collaboration with the European Organisation for Research and Treatment of Cancer (EORTC). The cooperative group sponsored clinical trial will evaluate DKN-01 in combination with atezolizumab (TECENTRIQ®) +/- paclitaxel in advanced esophagogastric malignancies and DKN-01 + atezolizumab in advanced biliary tract cancers at EORTC centers across Europe. Roche will supply atezolizumab to the EORTC for this study collaboration. “DKN-01 has shown promising activity in advanced esophagogastric and biliary tract cancers. Given the emerging role of Wnt/beta-catenin in immuno-oncology, we believe that DKN-01 could be a novel immunotherapy for these patients and look forward to evaluating its activity when combined with atezolizumab and paclitaxel,” commented Markus Moehler, M.D., Ph.D, Profes
Show less
Read more
Impact Snapshot
Event Time:
LPTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LPTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LPTX alerts
High impacting Leap Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LPTX
News
- Leap Therapeutics Announces $40 Million Private Placement [Yahoo! Finance]Yahoo! Finance
- Leap Therapeutics Announces $40 Million Private PlacementPR Newswire
- Leap Therapeutics, Inc. (NASDAQ: LPTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
- Leap Therapeutics, Inc. (NASDAQ: LPTX) had its price target lowered by analysts at Robert W. Baird from $11.00 to $9.00. They now have an "outperform" rating on the stock.MarketBeat
- Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
LPTX
Earnings
- 3/18/24 - Beat
LPTX
Sec Filings
- 4/19/24 - Form SC
- 4/19/24 - Form 3
- 4/11/24 - Form 8-K
- LPTX's page on the SEC website